Last reviewed · How we verify
Nelarabine injection
Nelarabine is a prodrug that is converted to arabinosyl guanine, which inhibits ribonucleotide reductase and DNA synthesis, leading to apoptosis in T-cell malignancies.
Nelarabine is a prodrug that is converted to arabinosyl guanine, which inhibits ribonucleotide reductase and DNA synthesis, leading to apoptosis in T-cell malignancies. Used for T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoblastic lymphoma (T-LBL).
At a glance
| Generic name | Nelarabine injection |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | Purine analog antimetabolite |
| Target | Ribonucleotide reductase; deoxyribonucleotide synthesis pathway |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Nelarabine is a purine analog prodrug that is metabolized to arabinosyl guanine (ara-G), which accumulates in T-lymphoid cells and inhibits ribonucleotide reductase, disrupting deoxyribonucleotide synthesis. This leads to depletion of deoxyadenosine triphosphate pools and triggers apoptosis in T-cell leukemias and lymphomas. The drug is particularly effective in T-cell malignancies due to high levels of deoxycytidine kinase in these cells.
Approved indications
- T-cell acute lymphoblastic leukemia (T-ALL)
- T-cell lymphoblastic lymphoma (T-LBL)
Common side effects
- Neurotoxicity (peripheral neuropathy, seizures)
- Myelosuppression (anemia, thrombocytopenia, neutropenia)
- Nausea and vomiting
- Fatigue
- Infection
Key clinical trials
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (PHASE2, PHASE3)
- The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma (PHASE3)
- Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma (PHASE2)
- Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma (PHASE1)
- Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nelarabine injection CI brief — competitive landscape report
- Nelarabine injection updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI